You are here

Article info

Article menu
Basic tumor immunology
Original research
STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

Authors

  • Rebekka Bitsch Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Annina Kurzay Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Feyza Özbay Kurt Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, GermanyFaculty of Biosciences, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Carolina De La Torre NGS Core Facility, Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Samantha Lasser Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, GermanyFaculty of Biosciences, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Alisa Lepper Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Alina Siebenmorgen Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Verena Müller Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Peter Altevogt Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Jochen Utikal Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  • Viktor Umansky Skin Cancer Unit/ Department of Dermatology, Venerology and Allergology, German Cancer Research Center (DKFZ), University Medical Centre Mannheim, Heidelberg, Mannheim, GermanyMannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, GermanyDKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Viktor Umansky; V.Umansky{at}dkfz-heidelberg.de
View Full Text

Citation

Bitsch R, Kurzay A, Özbay Kurt F, et al
STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
Journal for ImmunoTherapy of Cancer 2022;10:e004384. doi: 10.1136/jitc-2021-004384

Publication history

  • Accepted February 21, 2022
  • First published March 17, 2022.
Online issue publication 
March 17, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.